UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-39461

NANO-X IMAGING LTD

Ofer Tech Park

94 Shlomo Shmeltzer Road

Petach Tikva

Israel 4970602

(Address of principal executive office)

Indicate by check mark whether the registrantfiles or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

On November 19, 2025, NANO-X IMAGING LTD issueda press release, a copy of which is attached hereto as Exhibit 99.1, and incorporated herein by reference.

EXHIBIT INDEX

SIGNATURES

Pursuant to the requirementsof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereuntoduly authorized.

Date: November 19, 2025

Exhibit 99.1

Nanox Reaches Agreement with Vaso Corporation to Acquire VasoHealthcareIT, Accelerating U.S. Rollout of AI Solutions

PETACH TIKVA, Israel, Nov. 19, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGINGLTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announcedthat the parties have agreed on the terms and conditions pursuant to which Nanox will acquire VasoHealthcare IT Inc. (“VHC IT”)from Vaso Corporation (“Vaso”) (OTCQX: VASO), subject to certain conditions.

This transaction is intended to accelerate deploymentof Nanox’s AI solutions across U.S. healthcare facilities and is expected to be executed and completed within a couple of weeks.

VHC IT is a healthcare information technology provider serving hospitalsand healthcare providers across the United States, with a team of professionals specializing in healthcare IT implementation. Its capabilitiesinclude healthcare systems integration, workflow optimization, data migration, user training, and nationwide go-live support for medicalimaging.

Under the terms of the proposed acquisition, VHC IT’s establishedoperational and customer-support infrastructure will be integrated with Nanox.AI’s FDA-cleared AI solutions that analyze routineCT scans for indicators of chronic diseases. This integration, once completed, will enable faster deployment and adoption while reducingtime-to-value for healthcare providers. VHC IT team’s, expertise and long-standing customer relationships are expected to supportthe Company’s U.S. commercial expansion.

Under the terms of the proposed transaction, Nanox will acquire VHCIT for a total consideration of up to $800,000, consisting of a $200,000 cash payment at closing and up to $600,000 in performance-basedearnout payments over a period of up to two years, contingent upon revenue retention targets with respect to existing customers.

“As we scale our AI business in the U.S., deployment pace andimplementation quality are critical to success,” said Erez Meltzer, CEO and Acting Chairman of Nanox. “Bringing these capabilitiesin-house will allow us to control the entire customer experience—from software delivery through go-live support. This acquisitionwill accelerate our ability to onboard new customers quickly and efficiently.”

Dr. Jun Ma, President and Chief Executive Officer of Vaso, said, “Webelieve that upon its execution, this transaction will be a positive development for our shareholders and will provide a strong futurefor the VasoHealthcare IT team as part of Nanox.”

About Nanox.AI

Nanox.AI is the deep-learning medical imaging analytics subsidiaryof Nanox. Nanox.AI solutions are developed to target highly prevalent chronic and acute diseases affecting large populations around theworld. Leveraging AI, Nanox.AI helps clinicians extract valuable and actionable clinical insights from medical imaging that otherwisemay go unnoticed, potentially initiating further medical assessment to establish individual preventative care pathways for patients. Formore information, please visit www.nanox.vision/ai.

About Nanox

Nanox (NASDAQ: NNOX) is focused on driving the world’s transitionto preventive health care by bringing a full solution of affordable medical imaging technologies based on advanced AI and proprietarydigital X-ray source.

Nanox’s vision encompasses expanding the reach of Nanox technologyboth within and beyond hospital settings, providing a seamless end-to-end solution from scan to diagnosis, leveraging AI to enhance theefficiency of routine medical imaging technology and processes, in order to improve early detection and treatment and maintaining a clinicallydriven approach. The Nanox ecosystem includes Nanox.ARC – a multi-source digital tomosynthesis system that is cost-effective anduser-friendly; Nanox.AI LTD – an AI-based suite of algorithms that augment the readings of routine CT imaging to highlight earlysigns often related to chronic diseases; Nanox.CLOUD – a cloud-based software platform that manages and stores data collected byNanox devices, and provides users with tools for in-depth imaging analysis; Nanox.MARKETPLACE – a proprietary decentralized marketplacethrough Nanox’s subsidiary, USARAD Holdings Inc., that provides remote access to radiology and cardiology experts, and a comprehensiveteleradiology services platform. By improving early detection and treatment, Nanox aims to enhance better health outcomes worldwide. Formore information, please visit www.nanox.vision.

About Vaso

Vaso Corporation (OTCQX: VASO), headquartered in Plainview, New York,is a diversified organization with three core businesses operating as wholly-owned subsidiaries: VasoHealthcare, the professional salesservice arm for GEHealthCare’s diagnostic imaging and ultrasound products; VasoTechnology, an information technology and managedconnectivity leader serving customers in healthcare provision and other sectors; and VasoMedical, the designer and manufacturer of proprietarymedical devices including Biox series devices and the developer and operator of the ARCS cloud-based SaaS platform.

For additional information, please visit www.vasocorporation.com orcontact us at info@vasocorporation.

Forward-Looking Statements

This press release may containforward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained inthis press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to theability to execute and consummate the transaction, the ability to successfully integrate VHC IT following the acquisition as well asto improve deployment speed pace and implementation quality, the initiation, timing, progress and results of the Company’sresearch and development, manufacturing, and commercialization activities with respect to its X-ray source technology and theNanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of theCompany and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as“can,” “might,” “believe,” “may,” “estimate,” “continue,”“anticipate,” “intend,” “should,” “plan,” “should,” “could,”“expect,” “predict,” “potential,” or the negative of these terms or other similar expressions.Forward-looking statements are based on information the Company has when those statements are made or management’s good faithbelief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performanceor results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could causeactual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to completedevelopment of the Nanox System; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology forcommercial applications; (iii) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt andmaintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agenciesworldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (iv) Nanox’s ability torealize the anticipated benefits of the acquisitions, which may be affected by, among other things, competition, brand recognition,the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (v) Nanox’s abilityto enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture theNanox.ARC; (vi) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (vii) Nanox’sexpectations regarding collaborations with third-parties and their potential benefits; (viii) Nanox’s ability to conductbusiness globally; (ix) changes in global, political, economic, business, competitive, market and regulatory forces; (x) risksrelated to the current war between Israel and Hamas and any worsening of the situation in Israel; (xi) risks related to businessinterruptions resulting from the COVID-19 pandemic or similar public health crises, among other things; and (xii) potentiallitigation associated with our transactions.

For a discussion of other risks and uncertainties, and other importantfactors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see thesection titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequentfilings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statementsincluded in this press release. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statementsafter the date of this press release to conform these statements to actual results or to changes in the Company’s expectations.

Contacts

Media Contact:

Ben Shannon

ICR Healthcare

NanoxPR@icrinc.com

Investor Contact:

Mike Cavanaugh

ICR Healthcare

mike.cavanaugh@icrhealthcare.com